Sinomenine ( DrugBank: Sinomenine )
2 diseases
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 46 | 悪性関節リウマチ | 1 |
| 222 | 一次性ネフローゼ症候群 | 2 |
46. 悪性関節リウマチ
臨床試験数 : 4,356 / 薬物数 : 2,567 - (DrugBank : 415) / 標的遺伝子数 : 192 - 標的パスウェイ数 : 228
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ChiCTR-IPR-15007415 | 2015-11-20 | 2015-11-19 | Study of Sinomenine Hydrochloride in the treatment of rheumatoid arthritis | Study of Sinomenine Hydrochloride in the treatment of rheumatoid arthritis | Rheumatoid arthritis | treatment group:sinomenine hydrochloride combined with MTX;controlled group:LEF combined with MTX; | Guangdong Provincial Hospital of Chinese Medicine | NULL | Recruiting | Both | treatment group:25;controlled group:25; | China |
222. 一次性ネフローゼ症候群
臨床試験数 : 310 / 薬物数 : 295 - (DrugBank : 117) / 標的遺伝子数 : 63 - 標的パスウェイ数 : 194
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ITMCTR2100004997 | 2021-07-01 | 2021-06-28 | Clinical and basic research of therapy with sinomenine for pimary membranous nephropathy | Clinical and basic research of therapy with sinomenine for pimary membranous nephropathy | PRIMARY MEMBRANOUS NEPHROPATHY | control group:Placebo 120mg orally intake twice a day;experimental group:Sinomenine 120mg orally intake twice a day; | Macau University of Science and Technology | NULL | Pending | 18 | 70 | Both | control group:80;experimental group:80; | Phase 4 | China |
| 2 | ChiCTR2100047996 | 2021-07-01 | 2021-06-28 | Clinical and basic research of therapy with sinomenine for pimary membranous nephropathy | Clinical and basic research of therapy with sinomenine for pimary membranous nephropathy | PRIMARY MEMBRANOUS NEPHROPATHY | experimental group:Sinomenine 120mg orally intake twice a day;control group:Placebo 120mg orally intake twice a day; | Macau University of Science and Technology | NULL | Pending | 18 | 70 | Both | experimental group:80;control group:80; | Phase 4 | China |